Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum93815ArticlesСтатьиResearch ArticleAntagonisty kal'tsiya v lechenii arterial'noy gipertonii: mesto lerkanidipinaАнтагонисты кальция в лечении артериальной гипертонии: место лерканидипинаMinushkinaL. OМинушкинаЛ. ОФГБУ Учебно-научный медицинский центр УД Президента РФ, Москва15052013155VOL 15, NO5 (2013)ТОМ 15, №5 (2013)5928122021Copyright ©; 2013, Consilium MedicumCopyright ©; 2013, ООО "Консилиум Медикум"2013Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/93815

Антагонисты кальция начали использовать в лечении артериальной гипертонии (АГ) с 1970-х годов, и в настоящее время этот класс препаратов относится к числу основных в лечении данного заболевания. Современные антагонисты кальция благодаря своим фармакологическим особенностям хорошо переносятся, что способствует хорошей приверженности больных лечению. Доказана эффективность антагонистов кальция не только как средств для снижения артериального давления (АД), но и как препаратов, влияющих на риск неблагоприятных исходов. Ряд метаанализов исследований с использованием препаратов этой группы показал, что антагонисты кальция имеют определенные преимущества перед препаратами других групп по предотвращению цереброваскулярных событий. Вместе с тем группа антагонистов кальция неоднородна и отличается по своему химическому строению, особенностям фармакокинетики и фармакодинамики. Лерканидипин (Занидип®-Рекордати, Recordati Ireland Ltd) относится к дигидроперидиновым антагонистам кальция. В настоящем обзоре представлены основные исследования, доказывающие эффективность этого препарата.

Álvarez C, Gómez E, Simón M et al. Differences in lercanidipine systemic exposure when administered according to labelling: in fasting state and 15 minutes before food intake. Eur J Clin Pharmacol 2012; 68 (7): 1043–7.Van Zwieten P.A. The pharmacological properties of lipophilic calcium antagonists. Blood Press (Suppl.) 1998; 2: 5–9.Corsini A, Accomazzo M.R, Canavesi M et al. The new calcium antagonist lercanidipine and its enantiomers affect major processes of atherogenesis in vitro: is calcium entry involved? Blood Press (Suppl.) 1998; 2: 18–22.Guarneri L, Angelico P, Ibba M et al. Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine. Arzneimittelforschung 1996; 46 (1): 15–24.Paterna S, Licata A, Arnone S et al. Lercanidipine in two different dosage regimens as a sole treatment of severe essential hypertension. J Cardiovasc Pharmacol 1997; 29: 50–3.Omboni S, Zanchetti A. Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. J Hypertens 1998; 16: 1831–8.Cafiero M, Giasi M. Long - term treatment with lercanidipine in patients with mild and moderate hypertension. J Cardiovasc Pharmacol 1997; 29: 45–9.Circo A. Active dose findings in a double - blind placebo - controlled design in patients with mild and moderatehypertension. J Cardiovasc Pharmacol 1997; 29: 21–5.Giorgio L. Viviani. Lercanidipine in Type II Diabetic Patients With Mild to Moderate Arterial Hypertension. J Cardiovasc Pharmacol 2002; 40: 133–9.Cleophas T.J, van Ouwerkerk B.M, van der Meulen J, Zwinderman A.H. Diabetics with hypertension not controlled with ACE inhibitors: alternate therapies. Angiology 2001; 52 (7): 469–75.Romito R, Pansini M.I, Perticone F et al. Comparative effect of lercanidipine, felodipine, and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercanidipine in Adults (LEAD) Study. J Clin Hypertens (Greenwich) 2003; 5 (4): 249–53.Bargallo Sangiorgi G, Putignano E, Calcara L et al. Efficacy and tolerability of lercanidipine vs captopril in patients with mild and moderate hypertension in a double - blind controlled study. J Cardiovascul Pharmacol 1997; 29: 36–9.James I.G, Jones A, Davies P. A randomised, double - blind, double - dummy comparison of the efficacy and tolerability of lercanidipine tablets and losartan tablets in patients with mild to moderate essential hypertension. J Hum Hypertens 2002; 16 (8): 605–10.Mc Clellan K.J, Jarvis B. Lercanidipine: a review of its use in hypertension. Drugs 2000; 60 (5): 1123–40.Campo C, Saavedra J, Segura J et al. Correlations of smoothness index and trough - to - peak ratio with left ventricular mass index changes induced by lercanidipine in hypertensive patients. A pilot trial. Minerva Med 2005; 96 (5): 365–71.Taddei S, Virdis A, Ghiadoni L et al. Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertension. Hypertension 2003; 41 (4): 950–5.Grassi G, Quarti-Trevano F, Scopelliti F et al. Effects of long - term lercanidipine or hydrochlorothiazide administration on hypertension - related vascular structural changes. Blood Press 2006; 15 (5): 268–74.Menne J, Park J.K, Agrawal R et al. Cellular and molecular mechanisms of tissue protection by lipophilic calcium channel blockers. Faseb J 2006; 20 (7): 994–6.Dalla Vestra M, Pozza G, Mosca A et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina). Diabetes Nutr Metab 2004; 17 (5): 259–66.Poncelet P, Ribstein J, Goullard L et al. Efficacy and acceptability of lercanidipine are not age dependent in patients with essential hypertension: the AGATE study. Ann Cardiol Angeiol (Paris) 2004; 53 (3): 123–30.Ninci M.A, Magliocca R, Malliani A. Efficacy and tolerability of lercanidipine in elderly patients with mild to moderate hypertension in a placebo - controlled, double - blind study. J Cardiovasc Pharmacol 1997; 29: S40–4.Barbagallo M, Barbagallo Sangiorgi G. Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hyperte nsion. Aging (Milano) 2000; 12 (5): 375–9.Mackenzie I.S, Mc Eniery C.M, Dhakam Z et al. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension 2009; 54 (2): 409–13.Barrios V, Navarro A, Esteras A et al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE Study. Eficacia de Lercanidipino y su Perfil de Seguridad. Blood Press 2002; 11 (2): 95–100.Hollenberg N.K. Observations on the safety of lercanidipine: adverse event data from placebo - controlled trials. Am J Hypertens 2002; 15: 58A–59A.Leonetti G, Magnani B, Pessina AC et al. Tolerability of long - term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens 2002; 15 (11): 932–40.Borghi C, Prandin M.G, Dormi A, Ambrosioni E. Study group of the regional Unit of the Italian Society of Hypertension. 2003. Improved Tolerability of the dihydropyridine calcium - channel antagonist lercanidipine: the lercanidipine challenge trial. Blood Press (Suppl. 1): 14–21.Burnier M, Gasser U.E. Effi cacy and tolerability of lercanidipine in patients with hypertension: results of a Phase IV study in general practice. Expert Opin Pharmacother 2007; 8: 2215–23.